Asembia AXS26: What Does the Next Phase of Specialty Pharma Look Like?

In the second part of their interview with Pharmaceutical Commerce at Asembia AXS26, Miranda Delatore, VP, Product, and Megan Wetzel, VP, Product, Access and Affordability, at CoverMyMeds discuss how the specialty pharmacy landscape continues to evolve as patient journeys grow more complex and new technologies reshape access workflows. The conversation focuses on how specialty pharmacies, manufacturers, and other stakeholders are adapting to increasing scale, expanding specialty pipelines, and shifting regulatory expectations.

Delatore describes specialty pharmacy as an area that has changed rapidly in recent years, particularly as access challenges become more complex. She points to the growing role of technology and automation, noting that solutions such as AI are increasingly becoming standard components of the access process. As specialty therapies and patient journeys continue to evolve, she says pharmacies will need to adjust how they manage access and support patients starting therapy.

The discussion also explores the forces likely to shape the industry moving forward. Delatore highlights recent regulatory developments and the potential for greater standardization across industry partners in how medications are delivered and supported. Wetzel adds that the specialty pipeline remains strong, with manufacturers continuing to invest heavily in specialty-focused research and development.

Both speakers point to AI, automation, and scalability as areas manufacturers and specialty stakeholders will need to closely monitor. They note that as specialty therapies become more advanced, access and affordability solutions will play an increasingly important role in supporting patients throughout the treatment journey.

Watch the first part of their interview with PC:

1. AI and the Access Gap: What’s Actually Changed?